請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33462
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 胡文聰(Andrew M. Wo) | |
dc.contributor.author | Chen-Ho Wang | en |
dc.contributor.author | 王成禾 | zh_TW |
dc.date.accessioned | 2021-06-13T04:41:52Z | - |
dc.date.available | 2016-08-03 | |
dc.date.copyright | 2011-08-03 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-27 | |
dc.identifier.citation | 1 Hatok, J. et al. In vitro assays for the evaluation of drug resistance in tumor cells. Clin Exp Med 9, 1-7, doi:DOI 10.1007/s10238-008-0011-3 (2009).
2 Bown, N. P. et al. Cytogenetic abnormalities of small round cell tumours. Med Pediatr Oncol 23, 124-129 (1994). 3 Zubor, P. et al. Human epithelial growth factor receptor 2[lle655Val] polymorphism and risk of breast fibroadenoma. Eur J Cancer Prev 17, 33-38 (2008). 4 Samson, D. J. Chemotherapy Sensitivity and Resistance Assays: A Systematic Review. Journal of Clinical Oncology 22, 3618-3630, doi:10.1200/jco.2004.04.077 (2004). 5 Vonhoff, D. D. et al. Prospective Clinical-Trial of a Human-Tumor Cloning System. Cancer Res 43, 1926-1931 (1983). 6 Vonhoff, D. D. et al. A Southwest-Oncology-Group Study on the Use of a Human Tumor Cloning Assay for Predicting Response in Patients with Ovarian-Cancer. Cancer 67, 20-27 (1991). 7 Vonhoff, D. D., Forseth, B. J., Huong, M., Buchok, J. B. & Lathan, B. Improved Plating Efficiencies for Human-Tumors Cloned in Capillary Tubes Versus Petri Dishes. Cancer Res 46, 4012-4017 (1986). 8 Aliosman, F. & Beltz, P. A. Optimization and Characterization of the Capillary Human-Tumor Clonogenic Cell Assay. Cancer Res 48, 715-724 (1988). 9 Shaw, G. L. et al. Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res 53, 5181-5187 (1993). 10 Gazdar, A. F. et al. Correlation of Invitro Drug-Sensitivity Testing Results with Response to Chemotherapy and Survival in Extensive-Stage Small Cell Lung-Cancer - a Prospective Clinical-Trial. J Natl Cancer I 82, 117-124 (1990). 11 Cortazar, P. et al. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin Cancer Res 3, 741-747 (1997). 12 Mehta, R. S. et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Tr 66, 225-237 (2001). 13 Loizzi, V. et al. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189, 1301-1307, doi:Doi 10.1067/S0002-9378(03)00629-X (2003). 14 Maenpaa, J. U. et al. The Subrenal Capsule Assay in Selecting Chemotherapy for Ovarian-Cancer - a Prospective Randomized Trial. Gynecol Oncol 57, 294-298 (1995). 15 Griffin, T. W. et al. Initial Clinical-Trials of the Subrenal Capsule Assay as a Predictor of Tumor Response to Chemotherapy. Cancer 52, 2185-2192 (1983). 16 Tomoko, F. et al. Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Research (2000). 17 Tanino, H. et al. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Anticancer research 21, 4083-4086 (2001). 18 Mooney, D. J. et al. Engineering tumors with 3D scaffolds. Nature Methods 4, 855-860, doi:10.1038/Nmeth1085 (2007). 19 Faute, M. A. D. et al. Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastas 19, 161-168 (2002). 20 Zahir, N. & Weaver, V. M. Death in the third dimension: apoptosis regulation and tissue architecture. Curr Opin Genet Dev 14, 71-80 (2004). 21 Paik, S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 12, 631-635, doi:DOI 10.1634/theoncologist.12-6-631 (2007). 22 Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med 351, 2817-2826 (2004). 23 Lo, S. S. et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28, 1671-1676, doi:10.1200/JCO.2008.20.2119 (2010). 24 Wu, M.-H., Huang, S.-B. & Lee, G.-B. Microfluidic cell culture systems for drug research. Lab on a Chip 10, 939, doi:10.1039/b921695b (2010). 25 Hsiung, L.-C. et al. Dielectrophoresis-based cellular microarray chip for anticancer drug screening in perfusion microenvironments. Lab on a Chip (2011). 26 Hung, P. J., Lee, P. J., Sabounchi, P., Lin, R. & Lee, L. P. Continuous perfusion microfluidic cell culture array for high-throughput cell-based assays. Biotechnology and Bioengineering 89, 1-8, doi:Doi 10.1002/Bit.20289 (2005). 27 Sugiura, S., Edahiro, J., Kikuchi, K., Sumaru, K. & Kanamori, T. Pressure-driven perfusion culture microchamber array for a parallel drug cytotoxicity assay. Biotechnology and Bioengineering 100, 1156-1165, doi:Doi 10.1002/Bit.21836 (2008). 28 Tung, Y.-C. et al. High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. The Analyst 136, 473, doi:10.1039/c0an00609b (2011). 29 Yu, L., Chen, M. C. W. & Cheung, K. C. Droplet-based microfluidic system for multicellular tumor spheroid formation and anticancer drug testing. Lab on a Chip 10, 2424, doi:10.1039/c004590j (2010). 30 Wu, L. Y., Di Carlo, D. & Lee, L. P. Microfluidic self-assembly of tumor spheroids for anticancer drug discovery. Biomedical Microdevices 10, 197-202, doi:DOI 10.1007/s10544-007-9125-8 (2008). 31 Ye, N. N., Qin, J. H., Shi, W. W., Liu, X. & Lin, B. C. Cell-based high content screening using an integrated microfluidic device. Lab on a Chip 7, 1696-1704, doi:Doi 10.1039/B711513j (2007). 32 Wang, Z. H., Kim, M. C., Marquez, M. & Thorsen, T. High-density microfluidic arrays for cell cytotoxicity analysis. Lab on a Chip 7, 740-745, doi:Doi 10.1039/B618734j (2007). 33 Von Hoff, D. D. et al. Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 70, 1027-1041 (1981). 34 Kern, D. H. & Weisenthal, L. M. Highly Specific Prediction of Antineoplastic Drug-Resistance with an Invitro Assay Using Suprapharmacologic Drug Exposures. J Natl Cancer I 82, 582-588 (1990). 35 Nagourney, R. A., Link, J. S., Blitzer, J. B., Forsthoff, C. & Evans, S. S. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. Journal of Clinical Oncology 18, 2245-2249 (2000). 36 Nagourney, R. A. et al. Carboplatin plus Gemcitabine Repeating Doublet Therapy in Recurrent Breast Cancer. Clinical Breast Cancer 8, 432-435, doi:Doi 10.3816/Cbc.2008.N.052 (2008). 37 Weisenthal, L. M., Patel, N. & Rueff-Weisenthal, C. Cell culture detection of microvascular cell death in clinical specimens of human neoplasms and peripheral blood. J Intern Med 264, 275-287, doi:DOI 10.1111/j.1365-2796.2008.01955.x (2008). 38 Nagourney, R. A. et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 88, 35-39, doi:DOI 10.1006/gyno.2002.6855 (2003). 39 Bogden, A. E. et al. Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: six-day subrenal capsule assay. Cancer 48, 10-20 (1981). 40 Edelstein, M. B., Fiebig, H. H., Smink, T., Van Putten, L. M. & Schuchhardt, C. Comparison between macroscopic and microscopic evaluation of tumour responsiveness using the subrenal capsule assay. Eur J Cancer Clin Oncol 19, 995-1009 (1983). 41 Furukawa, T. et al. Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Res 20, 3657-3658 (2000). 42 Ohie, S. et al. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res 20, 2049-2054 (2000). 43 Kravtsov, V. D. A Novel Microculture Kinetic Assay (Mick Assay) for Malignant-Cell Growth and Chemosensitivity. Eur J Cancer 30A, 1564-1570 (1994). 44 Kravtsov, V. D., Greer, J. P., Whitlock, J. A. & Koury, M. J. Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias. Blood 92, 968-980 (1998). 45 Ballard, K. S. et al. Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment. J Gynecol Oncol 21, 45-49, doi:10.3802/jgo.2010.21.1.45 (2010). 46 Mi, Z. B. et al. Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients. Anticancer Research 28, 1733-1740 (2008). 47 Peters, D., Freund, J. & Ochs, R. L. Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther 4, 1605-1616, doi:10.1158/1535-7163.MCT-04-0311 (2005). 48 Ochs, R. L., Burholt, D. & Kornblith, P. The ChemoFx assay: an ex vivo cell culture assay for predicting anticancer drug responses. Methods Mol Med 110, 155-172, doi:10.1007/978-1-59745-339-4_6 (2005). 49 Shirota, Y. et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. Journal of Clinical Oncology 19, 4298-4304 (2001). 50 Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 16, 3537-3541 (1998). 51 Popat, S., Hubner, R. & Houlston, R. S. Systematic review of microsatellite instability and colorectal cancer prognosis. Journal of Clinical Oncology 23, 609-618, doi:Doi 10.1200/Jco.2005.01.186 (2005). 52 Gianni, L. et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. Journal of Clinical Oncology 23, 7265-7277, doi:Doi 10.1200/Jco.2005.02.0818 (2005). 53 Kondo, J. et al. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc Natl Acad Sci U S A 108, 6235-6240, doi:10.1073/pnas.1015938108 (2011). 54 Duffy, D. C., McDonald, J. C., Schueller, O. J. A. & Whitesides, G. M. Rapid prototyping of microfluidic systems in poly(dimethylsiloxane). Analytical Chemistry 70, 4974-4984 (1998). 55 Mehta, G. et al. Hard Top Soft Bottom Microfluidic Devices for Cell Culture and Chemical Analysis. Analytical Chemistry 81, 3714-3722, doi:Doi 10.1021/Ac802178u (2009). 56 Madri, J. A. & Williams, S. K. Capillary Endothelial Cell-Cultures - Phenotypic Modulation by Matrix Components. J Cell Biol 97, 153-165 (1983). 57 Folkman, J., Watson, K., Ingber, D. & Hanahan, D. Induction of Angiogenesis during the Transition from Hyperplasia to Neoplasia. Nature 339, 58-61 (1989). 58 St Croix, B. & Kerbel, R. S. Cell adhesion and drug resistance in cancer. Curr Opin Oncol 9, 549-556 (1997). 59 Desoize, B. & Jardillier, J. C. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hemat 36, 193-207 (2000). 60 Puccinelli, J. P., Su, X. & Beebe, D. J. Automated High-Throughput Microchannel Assays for Cell Biology: Operational Optimization and Characterization. Journal of the Association for Laboratory Automation 15, 25-32, doi:10.1016/j.jala.2009.10.002 (2010). 61 Culbertson, C. T., Jacobson, S. C. & Ramsey, J. M. Diffusion coefficient measurements in microfluidic devices. Talanta 56, 365-373, doi:Pii S0039-9140(01)00602-6 (2002). 62 Berthier, E., Warrick, J., Yu, H. & Beebe, D. J. Managing evaporation for more robust microscale assays : Part 2. Characterization of convection and diffusion for cell biology. Lab on a Chip 8, 860, doi:10.1039/b717423c (2008). 63 Urbanski, J. P., Thies, W., Rhodes, C., Amarasinghe, S. & Thorsen, T. Digital microfluidics using soft lithography. Lab on a Chip 6, 96-104, doi:Doi 10.1039/B510127a (2006). 64 Song, J. W. et al. Computer-controlled microcirculatory support system for endothelial cell culture and shearing. Analytical Chemistry 77, 3993-3999, doi:Doi 10.1021/Ac050131o (2005). 65 Heo, Y. S. et al. Characterization and resolution of evaporation-mediated osmolality shifts that constrain microfluidic cell culture in poly(dimethylsiloxane) devices. Analytical Chemistry 79, 1126-1134, doi:Doi 10.1021/Ac061990v (2007). 66 Lacroix, M. & Leclercq, G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Tr 83, 249-289 (2004). 67 Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival - Application to Proliferation and Cyto-Toxicity Assays. J Immunol Methods 65, 55-63 (1983). 68 Veneziani, B. M. et al. In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. Mol Cancer Ther 6, 3091-3100, doi:Doi 10.1158/1535-7163.Mct-07-0356 (2007). 69 Walker, G. M. & Beebe, D. J. A passive pumping method for microfluidic devices. Lab on a Chip 2, 131-134, doi:10.1039/b204381e (2002). 70 Beebe, D. J. & Berthier, E. Flow rate analysis of a surface tension driven passive micropump. Lab on a Chip 7, 1475-1478, doi:10.1039/b707637a (2007). 71 Lu, H. et al. Microfluidic shear devices for quantitative analysis of cell adhesion. Analytical Chemistry 76, 5257-5264, doi:Doi 10.1021/Ac049837t (2004). 72 Wang, D. & Lippard, S. J. Cellular processing of platinum anticancer drugs. Nature Reviews Drug Discovery 4, 307-320, doi:10.1038/nrd1691 (2005). 73 Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2, 1-17 (2002). 74 Flaim, C. J., Teng, D., Chien, S. & Bhatia, S. N. Combinatorial signaling microenvironments for studying stem cell fate. Stem Cells Dev 17, 29-39, doi:DOI 10.1089/scd.2007.0085 (2008). 75 Royer, H. D. et al. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem 283, 739-750, doi:10.1074/jbc.M706287200 (2008). 76 Elenbaas, R. M., Elenbaas, J. K. & Cuddy, P. G. Evaluating the Medical Literature .2. Statistical-Analysis. Ann Emerg Med 12, 610-620 (1983). 77 Paguirigan, A. L. & Beebe, D. J. From the cellular perspective: exploring differences in the cellular baseline in macroscale and microfluidic cultures. Integrative Biology 1, 182, doi:10.1039/b814565b (2009). 78 Berthier, E., Warrick, J., Yu, H. & Beebe, D. J. Managing evaporation for more robust microscale assays : Part 1. Volume loss in high throughput assays. Lab on a Chip 8, 852, doi:10.1039/b717422e (2008). 79 Hendrix, M. J., Seftor, E. A., Chu, Y. W., Trevor, K. T. & Seftor, R. E. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev 15, 507-525 (1996). 80 Dan, S. et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62, 1139-1147 (2002). 81 Cawkwell, L., Watson, M. B., Lind, M. J., Smith, L. & Drew, P. J. Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model. Acta Oncol 46, 651-658, doi:10.1080/02841860601156157 (2007). 82 Feng, L. I. et al. Improved potency of cisplatin by hydrophobic ion pairing. Cancer Chemoth Pharm 54, 441-448, doi:10.1007/s00280-004-0840-z (2004). 83 Dittrich, P. S. & Manz, A. Lab-on-a-chip: microfluidics in drug discovery. Nat Rev Drug Discov 5, 210-218, doi:10.1038/nrd1985 (2006). 84 Regehr, K. J. et al. Biological implications of polydimethylsiloxane-based microfluidic cell culture. Lab Chip 9, 2132-2139, doi:10.1039/b903043c (2009). 85 Toepke, M. W. & Beebe, D. J. PDMS absorption of small molecules and consequences in microfluidic applications. Lab Chip 6, 1484-1486, doi:10.1039/b612140c (2006). 86 Wang, J. Y. et al. Photocatalyzed Surface Modification of Poly(dimethylsiloxane) with Polysaccharides and Assay of Their Protein Adsorption and Cytocompatibility. Analytical Chemistry 82, 6430-6439, doi:10.1021/ac100544x (2010). 87 Sieuwerts, A. M. et al. Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells. J Natl Cancer I 101, 61-66, doi:10.1093/jnci/djn419 (2009). 88 Onitilo, A. A., Engel, J. M., Greenlee, R. T. & Mukesh, B. N. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7, 4-13, doi:10.3121/cmr.2008.825 (2009). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33462 | - |
dc.description.abstract | 化學治療是癌症的最主要治療方式之一,化療藥物的種類繁多,特定病患最適合的化療藥物選用在進行化學治療前尤其重要,若施予不適合病患的化療藥物,則會導致不佳的治療效果,使病患必須進行多次的化學治療,造成病患身體上的沉重負擔。
基於上述之原因,本研究發展一種可進行化學治療藥物測試實驗的微流體晶片,進行癌症病患檢體的化學藥物測試 (Chemosensitivity Microfluidic Assay, CheMA)。期望藉由自癌症病患病灶取出的檢體,在化學治療前進行個別病患的最適化療藥物種類與劑量的預測。本研究著重於有效利用自癌症病患取出的少量檢體,做最多有效的化學治療藥物測試,期望得以提升每一次化學治療的效果,實現有效地在手術前縮減腫瘤體積及手術後清除剩餘癌細胞。 檢體自病灶位置取出後,便經由處理製成配於培養液的細胞懸浮液並種入本研究中發展的微流體晶片,並施以兩種主要使用的乳癌化學治療藥物 (cisplatin, docetaxel) 進行藥物反應測試。藉由微流體技術,本藥物測試方法共僅需大約9,000顆細胞即可完成一次單一藥物化療藥物試驗。除了所需的細胞數目較低之外,為使植入的少量細胞可以在進行液體置換時有效的存留在晶片上,本元件設計一環形圍繞細胞植入區的微流道。藉由於微流道進行液體置換,可避免換液體所使用的工具直接碰觸到細胞,以此避免明顯的細胞數目改變,造成藥物測試結果的不準確。細胞被施以化學治療藥物四十八小時後,螢光染劑即置入以判定細胞在不同藥物濃度處理下的存活率。MCF7及MDA-MB-231細胞株的藥物反應測試實驗,在本研究中用以驗證本微流體晶片作為藥物測試平台的可行性。 根據細胞株的藥物測試實驗結果,在CheMA上進行之藥物測試實驗結果與96孔盤控制實驗結果之間,於統計上沒有顯著差異。此外,細胞株於兩種化療藥物處理下的IC50數值在兩平台上也相當接近。三個病患檢體藥物反應實驗也在本研究中使用CheMA進行。 簡言之,本微流體晶片及藥物敏感度檢測方法經由細胞株實驗後,在細胞數量極少的情況下進行藥物測試實驗的可行性即被驗證。藉由本研究所發展的微流體晶片及實驗方法,期望可以應用於病人檢體的藥物測試,以提供臨床醫師在藥物選用上的有效建議。 | zh_TW |
dc.description.abstract | There are many different kinds of anticancer drugs for chemotherapy nowadays. The most important issue to doctors is the choice of anticancer drug for specific patients. Once patients were treated with ineffective treatment, the patients would need further repeats of chemotherapy which was really harmful to patients.
In order to solve the problem stated above, we present a microfluidic device to conduct chemosensitivity microfluidic assay (CheMA) for primary cell-based individualized chemosensitivity profiling while consuming 9,000 cells for single reagent response assay. Cancer cells from patients were seeded into microfluidic device and treated with 3 concentrations of 2 major used anticancer drugs. Roughly, only 9,000 cells in total were required for a single drug response assay by CheMA. In addition, cells in units of microfluidic device were conserved by conducting solution exchange through surrounding microchannels. After drug treatment, cell viability was quantified by a tri-staining method to distinguish cancer cells, normal cells and dead cells. MCF7 and MDA-MB-231 cell lines were applied to anticancer drug screening to prove the feasibility of drug response assay by CheMA. No statistical significance was found in dose-responses between CheMA and 96-well plate controls. Furthermore, the IC50 values of cisplatin and docetaxel were similar between the two platforms. Moreover, the drug response of patient samples were conducted by CheMA with few cells demanded. Primary samples of breast cancer patients were also examined by CheMA. In short, CheMA could be applied to prediction of individual chemotherapy within days when the sizes of tumors were not enough for a complete traditional assay. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T04:41:52Z (GMT). No. of bitstreams: 1 ntu-100-R98543028-1.pdf: 2363972 bytes, checksum: 52467f9cccb483d8038af9a8b34ae992 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 謝辭 i
中文摘要 ii Abstract iv Contents vi 圖目錄 vii 表目錄 ix 1. Introduction 1 2. Design concepts of the microfluidic device 11 3. Experimental 15 3.1. Microfabrication 15 3.2. Assessment of the microfluidic device 17 3.3. Chemosensitivity microfluidic assay (CheMA) on breast cancer cell lines 26 3.4. Preparation of breast cancer tissues 28 3.5. Procedures of CheMA 30 3.6. Statistical analysis 34 4. Results and discussion 35 4.1. Characterization of the microwell slide 35 4.2. Chemosensitivity profiling of breast cancer cell lines by CheMA 46 4.3. Chemosensitivity of breast cancer tissues evaluated 59 5. Conclusion 78 6. Acknowledgement 79 7. Supplementary information 80 7.1. Holes punching with stainless tube 80 7.2. Volume of cell suspension optimization 82 7.3. The correlation between manual and auto quantification 86 7.4. The viability assessment by MTT assay 88 7.5. The tri-staining method 90 8. References 91 | |
dc.language.iso | en | |
dc.title | 微流體晶片應用於個人化乳癌化療藥物敏感性測定之研究 | zh_TW |
dc.title | Individualized Chemosensitivity Profiling of Breast Cancer Tissue Using a Microfluidic Assay | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃俊升(Chiun-Sheng Huang),林璟宏(Ching-Hung Lin) | |
dc.subject.keyword | 微流體,化療敏感性檢測,個人化化學治療,藥物反應檢測,初代細胞培養, | zh_TW |
dc.subject.keyword | Microfluidics,Chemosensitivity profiling,Individualized chemotherapy,Drug response assay,Primary cell culture, | en |
dc.relation.page | 96 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-27 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 應用力學研究所 | zh_TW |
顯示於系所單位: | 應用力學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 2.31 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。